EMA Survey To Gauge Pharma's Satisfaction With Its Medical Literature Monitoring Service
This article was originally published in SRA
The European Medicines Agency is inviting feedback from pharmaceutical companies using its medical literature monitoring service to gauge if they are satisfied with the operation of this new tool, which was created under the provisions of the EU pharmacovigilance legislation to reduce the administrative burden on companies1.
You may also be interested in...
The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.